首页> 外国专利> Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders

Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders

机译:人参提取物,人参皂苷和人参皂苷衍生物在制备治疗巨细胞病毒感染疾病的药物或保健产品中的用途

摘要

Disclosed is the use of a ginseng extract, a ginsenoside and a ginsenoside derivative in the preparation of a medicine or health care product for the treatment of human cytomegalovirus infection-related diseases. The related diseases comprise a patient suffering from cardiovascular and cerebrovascular diseases, organ transfers, being perinatal, tumors, burns, AIDS and other diseases being infected by the human cytomegalovirus during treatment. Experiments demonstrate that the ginseng extract, the ginsenoside and the ginsenoside derivative are significant and quickly effective in the treatment of diseases of human cytomegalovirus infections, are less toxic and have less side effects, so that same are a safe, efficient, stable medicine or health care product with a simple preparation process for treating human cytomegalovirus virus infections, and are suitable for industrial production and easily propagated. They provide a new source of medicine for treating human cytomegalovirus infections.
机译:公开了人参提取物,人参皂苷和人参皂苷衍生物在制备用于治疗人类巨细胞病毒感染相关疾病的药物或保健产品中的用途。相关疾病包括患有心血管和脑血管疾病,围产期器官转移,肿瘤,烧伤,AIDS和在治疗期间被人巨细胞病毒感染的其他疾病的患者。实验表明,人参提取物,人参皂苷和人参皂苷衍生物在治疗人类巨细胞病毒感染的疾病方面具有重要意义且迅速有效,而且毒性较小且副作用较小,因此它们是安全,有效,稳定的药物或保健品该护理产品具有用于治疗人巨细胞病毒感染的简单制备方法,适合工业化生产且易于繁殖。它们为治疗人类巨细胞病毒感染提供了新的医学来源。

著录项

  • 公开/公告号AU2016263260A1

    专利类型

  • 公开/公告日2018-01-18

    原文格式PDF

  • 申请/专利权人 LI FU;

    申请/专利号AU20160263260

  • 申请日2016-04-21

  • 分类号A61K36/9068;A61P31/12;

  • 国家 AU

  • 入库时间 2022-08-21 12:45:42

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号